Korean Journal of Clinical Laboratory Science (대한임상검사과학회지)

Korean Society for Clinical Laboratory Science (대한임상검사과학회)
권호 표지
DOI QR코드

DOI QR Code

Association between the Components of Metabolic Syndrome and Total Bilirubin at the Health Care Check Up in Korean Men and Women: Based on Adults Except for Diabetes and Hypertension

당뇨와 고혈압 환자를 제외한 건강검진을 실시한 한국 성인남녀의 대사증후군 구성요소와 총 빌리루빈간의 관련성

  • Shin, Kyung-A (Department of Clinical Laboratory Science, Shinsung University)
  • Received : 2018.04.23
  • Accepted : 2018.05.17
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Bilirubin has an anti-inflammatory effect as an endogenous antioxidant and has been reported to be inversely correlated with hypertension, diabetes, metabolic syndrome, and insulin resistance. On the other hand, there is a lack of research evaluating the association between bilirubin and metabolic syndrome compared to liver-specific indicators. This study examined the association between the total bilirubin and metabolic syndrome prevalence in Korean adults who underwent health screening compared to ALT and GGT. This cross sectional study included 22,568 adult males and females aged 20 years or older who underwent a health examination at the General Hospital of Gyeonggi Province from March 2015 to February 2018. Metabolic syndrome was diagnosed based on the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) guidelines. In both genders, the metabolic syndrome diagnosed group had higher liver enzymes, and the total bilirubin and direct bilirubin were lower than those without the metabolic syndrome risk factors. The serum total bilirubin showed a weak inverse correlation with abdominal obesity (r=-0.066 vs r=-0.055) and triglyceride (r=-0.127 vs r=-0.136) in both males and females, which is weaker than ALT and GGT The data were statistically significant. In addition, total bilirubin as well as ALT and GGT in both men and women were not predictors of the likelihood of developing metabolic syndrome.

빌리루빈은 내인성 항산화제로서 항염작용이 있으며, 고혈압, 당뇨병, 대사증후군 및 인슐린 저항성과 역상관 관계에 있다고 보고된다. 그러나 간 특이적 지표와 비교하여 빌리루빈과 대사증후군간의 관련성을 평가한 연구는 부족하다. 본 연구에서는 건강검진을 실시한 한국 성인남녀를 대상으로 ALT, GGT와 비교하여 총 빌리루빈과 대사증후군 유병률 사이의 관련성을 조사하고자 하였다. 이 횡단면 연구에는 2015년 3월부터 2018년 2월까지 경기도 소재 종합병원에서 건강검진을 실시한 20세 이상 성인남녀 22,568명이 포함되었다. American Heart Association/National Heart, Lung, and Blood Institute(AHA/NHLBI)의 지침에 따라 대사증후군을 진단하였다. 남녀 모두에서 대사증후군 위험요인이 없는 군보다 대사증후군 진단군에서 간 효소치가 높았으며, 총 빌리루빈과 직접 빌리루빈치는 낮게 나타났다. 남녀 모두에서 혈청 총 빌리루빈은 복부비만(r=-0.066 vs r=-0.055), 중성지방(r=-0.127 vs r=-0.136)과 약한 역상관 관계를 보였으며, 이는 ALT와 GGT보다 약한 관련성이었다. 또한 남녀 모두에서 ALT와 GGT뿐만 아니라 총 빌리루빈은 대사증후군 발생 가능성을 예측하는 지표는 아닌 것으로 나타났다.

Keywords

References

  1. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705-712. https://doi.org/10.1016/j.lfs.2009.02.026
  2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  3. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198:1-11. https://doi.org/10.1016/j.atherosclerosis.2008.01.001
  4. Erdogan D, Gullu H, Yildirim E, Tok D, Kirbas I, Ciftci O, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006;184:431-437. https://doi.org/10.1016/j.atherosclerosis.2005.05.011
  5. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:166-172.
  6. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med. 2008;121:781-788. https://doi.org/10.1016/j.amjmed.2008.03.045
  7. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, et al. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes. 2008;57:1526-1535. https://doi.org/10.2337/db07-1764
  8. Jo J, Yun JE, Lee H, Kim H, Jee SH. Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population. Endocrine. 2011;39:182-189. https://doi.org/10.1007/s12020-010-9417-2
  9. Li XH, Lin HY, Guan LY, Peng H, Wen MM, Cao YQ, et al. Direct bilirubin levels and risk of metabolic syndrome in healthy Chinese men. Biomed Res Int. 2017;2017:9621615.
  10. Oda E, Aizawa Y. Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women. Acta Diabetol. 2013;50:417-422. https://doi.org/10.1007/s00592-012-0447-5
  11. Perera S, Lohsoonthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. Association between elevated liver enzymes and metabolic syndrome among Thai adults. Diabetes Metab Syndr. 2008;2:171-178. https://doi.org/10.1016/j.dsx.2008.04.012
  12. Shin KA. The clinical implications of hepatic enzymes in metabolically healthy obese men. Korean J Clin Lab Sci. 2017;49:248-255. https://doi.org/10.15324/kjcls.2017.49.3.248
  13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  14. World Health Organization. The Asia-Pacific Perspective: Redefining obesity and its treatment. Sydney, Australia: health communications Australia; 2000. p19-20.
  15. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51:859-862. https://doi.org/10.1016/0006-2952(95)02395-X
  16. Guzek M, Jakubowski Z, Bandosz P, Wyrzykowski B, Smoczynski M, Jabloiska A, et al. Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population. Przegl Epidemiol. 2012;66:495-501.
  17. Wu Y, Li M, Xu M, Bi Y, Li X, Chen Y, et al. Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes. 2011;3:217-224. https://doi.org/10.1111/j.1753-0407.2011.00138.x
  18. Lee MJ, Jung CH, Kang YM, Hwang JY, Jang JE, Leem J, et al. Serum bilirubin as a predictor of incident metabolic syndrome: a 4-year retrospective longitudinal study of 6205 initially healthy Korean men. Diabetes Metab. 2014;40:305-309. https://doi.org/10.1016/j.diabet.2014.04.006
  19. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038-1044. https://doi.org/10.1161/01.ATV.0000161274.87407.26
  20. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56:1535-1543. https://doi.org/10.1373/clinchem.2010.151043
  21. Kappas A. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics. 2004;113:119-123. https://doi.org/10.1542/peds.113.1.119
  22. Huang SS, Chan WL, Leu HB, Huang PH, Lin SJ, Chen JW. Serum bilirubin levels predict future development of metabolic syndrome in healthy middle-aged nonsmoking men. Am J Med. 2015;128:1138.